mammalian target or rapamycin
Mammalian target of rapamycin signaling in diabetic cardiovascular disease
... The mammalian target of rapamycin (mTOR) is a serine/ threonine protein kinase that controls cellular growth as well as cellular homeostasis ...of rapamycin-resistant TOR mutants that resulted ...
8
New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists
... of mammalian target of rapamycin inhibitors for cancer treatment Based on preclinical studies suggesting that inhibition of mTOR has antiproliferative effects in a variety of cancer models, clinical ...
6
Role of mammalian target of rapamycin (mTOR) signalling in BeWo trophoblast differentiation and fusion
... The mammalian target of rapamycin (mTOR) acts as a placental growth signalling sensor, and this has been implicated in the pathophysiology of diseases such as intrauterine growth restriction ...
158
Regulation of signalling circuitry downstream of mTORC1(mammalian target of Rapamycin)
... in mammalian translation initiation was confirmed when it was demonstrated that expression of a rapamycin- resistant FRAP/mTOR protein confers rapamycin resistance to 4E-BP1 phosphorylation ...a ...
17
Inhibition of mammalian target of rapamycin improves neurobehavioral deficit and modulates immune response after intracerebral hemorrhage in rat
... of rapamycin on the neurobehavior of ICH rats To determine the role of mTOR signaling after ICH, rapamycin, an mTOR inhibitor, was injected intraperito- neally at 1 hour after ...μg/kg rapamycin- ...
13
Inhibiting the Mammalian Target of Rapamycin Blocks the Development of Experimental Cerebral Malaria
... PbA-infected, rapamycin- treated mice (an average of 2 per section) ...with rapamycin daily beginning on day 4 ...with rapamycin prevents experimental cerebral malaria ...with rapamycin (Rapa ...
17
Autophagic/lysosomal dysfunction in Alzheimer’s disease
... activated mammalian target of rapamycin (mTOR)-dependent au- tophagy while pharmacologic block of autophagy pre- vented the cystatin C-induced protein clearance ...
9
Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer
... transplantation. Rapamycin has proven to be a versatile compound with several seemingly unrelated properties, including antifungal, immunosuppressive, and ...that rapamycin inhibited cell growth in tumor ...
7
High DEPTOR expression correlates with poor prognosis in patients with esophageal squamous cell carcinoma
... containing mammalian target of rapamycin (mTOR)-interacting protein (DEPTOR) abnormal expres- sion may be associated with resistance to chemotherapy in breast cancer patients; these authors also ...
7
Combining molecular targeted agents with radiation therapy for malignant gliomas
... to target important molecular pathways associated with aberrant activation or suppression of cellular signal transduction pathways involved in gliomagenesis, including epidermal growth factor receptor, vascular ...
17
Next generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
... Mammalian target of rapamycin (mTOR) is a PI3K-related kinase that regulates cell growth, proliferation, and survival via mTOR complex 1 (mTORC1) and ...
12
EAAT3 promotes amino acid transport and proliferation of porcine intestinal epithelial cells
... Excitatory amino acid transporter 3 (EAAT3, encoded by SLC1A1) is an epithelial type high-affinity anionic amino acid transporter, and glutamate is the major oxidative fuel for intestinal epithelial cells. This study ...
12
Rare frequency of gene variation and survival analysis in thymic epithelial tumors
... No targeted drugs are approved in TET due to its rarity and lack of explicit molecular targets. Patients with advanced/ metastatic thymoma or thymic carcinoma benefited from mammalian target of ...
6
Systemic treatment of advanced papillary renal cell carcinoma: Where next?
... Bernard Escudier and colleagues are to be congratulated for successfully recruiting and reporting the RAPTOR study in this edition of EJC (1). This phase 2 trial evaluated the efficacy and safety of the orally ...
6
A mechanistic role for the chromatin modulator, NAP1L1, in pancreatic neuroendocrine neoplasm proliferation and metastases
... NAP1L1 knockdown and tumor cell signaling in vitro Initially, we examined the effect of NAP1L1 silencing in the BON cell line. NAP1L1 was silenced 3-fold (p < 0.001) as demonstrated at both protein (Figure 1A) and ...
12
Mathematical Modelling of Metabolic Regulation in Aging
... Abstract: The underlying cellular mechanisms that characterize aging are complex and multifaceted. However, it is emerging that aging could be regulated by two distinct metabolic hubs. These hubs are the pathway defined ...
20
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients
... (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling axis plays a central role in cell proliferation, growth, and survival under physiological ...validated target for innovative cancer ...
15
Aberrant expression of microRNA-99a and its target gene mTOR associated with malignant progression and poor prognosis in patients with osteosarcoma
... Background: The mammalian target of rapamycin (mTOR) has been reported to act as a target gene of microRNA (miR)-99a in various cancer cells and identified as an independe[r] ...
9
Characterisation of PLD activity in real time
... the mammalian target of rapamycin (mTOR – Fang et ...The rapamycin-sensitive mTORC1 has been extensively studied and is regulated by a range of factors including grwoth factors, mitogens and ...
354
A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma
... mTOR: Mammalian target of rapamycin; NET: Neuroendocrine tumor; NMP: N-Methyl-2-pyrrolidone; NSG: Non-obese severe combined immunodeficiency gamma null mouse; NSG-H: NSG hypoxanthine phosphoribosyl ...
17